;
![]()
healthcare & life sciences
Schoenherr's experts provide straight-to-the-point legal advice in all legal matters in the healthcare & life sciences industry.
Schoenherr's healthcare group draws on a breadth of experience across the firm's practice areas. We combine specialist knowledge and experience with the insights and track-record of our market-leading transactional practice.
Our healthcare & life sciences team covers a wide range of subjects, including pharmaceuticals, biochemistry, chemicals, e-health, cosmetics, medical devices, toys, tobacco products, food and feed.
Partners Andreas Natterer and Paweł Halwa lead and coordinate the Schoenherr expert team. We act for and advise all stakeholders active in the healthcare, life sciences, biotech and pharma sectors. Areas of particular expertise are regulatory life sciences work and transactional advice regarding targets in the healthcare and life sciences industry.
legal areas
Working closely and in integrated teams with specialists in:
- crisis management
- compliance & internal investigations
- wcc & criminal defence
- eu & competition
- regulatory
- data protection
- ip & unfair commercial practices
- it & technology law
- corporate & reorganisations
- m&a
our services
Our full-service offering in the healthcare & life sciences sector covers:
- medicinal products
- drugs, (narcotic) substances
- food and feed
- tobacco and tobacco substitutes
- medical devices
- genetically modified organisms
- chemicals
- cosmetics
- medical and care institutions advice as well as hospitals
Our advisory covers inter alia:
- transactional advice including m&a, banking & finance, capital markets as well as real estate (development)
- advising on the establishment, operation and transfer of group practices, primary health care units and outpatient clinics
- assisting strategic and financial investors in respect of the acquisition of outpatient clinics as well as out- and inpatient hospitals
- m&a and other transactional advice in connection with investments in and the takeover of targets operating in the health care and life sciences industries
- advising on the qualification and classification of software as medical devices, on telemedicine, e-health and e-medication
- advising on contracts for clinical trials, quality agreements, licensing, collaboration, research and other agreements relevant to the sector
- supporting medical device, pharmaceutical and medical supply manufacturers in relation to regulatory clearance proceedings, product marketing and distribution, and business compliance
- providing guidance on the exploitation, enforcement and defence of ip rights
- representing clients in medical malpractice claims
- investigating corporate crimes, compliance violations, confidential information leaks and breach of legal duties
- crisis management such as advising in product recalls on national and international levels
- representation before national/European authorities/courts
news
roadmap
Pharmaceuticals: challenges in entering Bulgaria's wholesale medicinal market
The pharmaceutical market in Bulgaria is a dynamic and rapidly growing sector, driven by increasing healthcare demands and a robust regulatory framework. It features a competitive mix of local and international players, with a significant presence of generic and innovative medicinal products. The push for generic medicinal products has also led to a rise in previously limited patent-related cases and revocation proceedings. However, the wholesale market remains crucial for ensuring the availability and distribution of medicinal products throughout the country.
publication
to the point: technology & digitalisation l January 2025
Welcome to the January edition of Schoenherr's to the point: technology & digitalisation newsletter!
newsletter
Happy New Regulation - The beginning of 2025 fires the starting gun for the new Health Technology Assessment Regulation
Health technologies, such as pharmaceuticals, medical devices and in-vitro diagnostics, play a key role in the success and progress of our healthcare system. Therefore, it is important to ensure health protection when using these technologies and to promote innovation. The economic aspect should not be underestimated either, as healthcare expenditure amounted to approx. 11 % of gross domestic product in Austria and approx. 10.4 % of gross domestic product in the EU in 2023.
info corner
coronavirus info corner
The coronavirus presents us with completely new challenges. With the coronavirus info corner we aim to provide specifics about certain legal aspects surrounding Covid-19.
team
our team
Schoenherr's healthcare & life sciences team consists of experienced lawyers across all our CEE offices.